Skip to main content

NUEVAS ESTRATEGIAS PARA MONITORIZAR LA ENFERMEDAD MINIMA RESIDUAL (EMR) EN LA LEUCEMIA LINFATICA CRONICA.

PI19/00753

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia, Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy

  • Arguello-Tomas, Miguel|||0000-0002-3329-4151
  • Mozas, Pablo|||0000-0001-9528-4971
  • Albiol, Nil|||0000-0003-2942-1362
  • López-Esteban, Miguel
  • Sierra, Jorge|||0000-0002-7966-0356
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Martínez-Laperche, Carolina
  • Moga, Esther|||0000-0003-4264-6910
  • Piñeyroa, Juan A.
  • Delgado, Julio|||0000-0002-5157-4376
  • Osorio, Santiago
  • Moreno, Carol|||0000-0003-3275-0271
Background: Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However, some patients require intervention shortly after diagnosis. In the past decade, several risk scores (RS) have been developed to predict disease progression, yet some patients are misclassified. On the other hand, IGHV subset 2 (IGHV2) predicts poor outcomes. Methods: A retrospective and multicentric study was conducted to compare the accuracy of five different RS (IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno) to predict disease progression in 781 stage A previously untreated patients with CLL. As an exploratory analysis, it was further investigated whether the inclusion of the IGHV2 as a poor prognostic parameter improved the accuracy of RS. Results: All the scores identified a similar group of patients with CLL in early stage with low-, intermediate-, and high-risk progression. Discrimination was high and similar in all RS (c-index = 0.74-0.79, area under the curve = 0.7-0.75), as well as calibration (p =.98) and parsimony, although CLL-IPI showed the best results (Akaike information criterion = 441). A total of 34.4% of patients were categorized within the same RS and concordance was at least moderate between RS. Conclusion: Moreover, the results suggest that IGHV2 may improve the accuracy of RS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia

  • Arguello-Tomas, Miguel|||0000-0002-3329-4151
  • Lynton-Pons, Elionor|||0000-0001-5375-7195
  • Albiol, Nil|||0000-0003-2942-1362
  • López Ferrer, Anna|||0000-0002-2121-963X
  • Sierra, Jorge|||0000-0002-7966-0356
  • Moga, Esther|||0000-0003-4264-6910
  • Moreno, Carol|||0000-0003-3275-0271
Background: Autoimmune disorders (AIDs) are frequent in patients with chronic lymphocytic leukemia (CLL). There is little information on the clinical characteristics and pathogenesis of nonhematologic AIDs in patients with CLL, although both entities present immunologic alterations in their clinical onset. Methods: This single-center series included 907 patients with CLL who had a median follow-up of 6.6 years (range, 0.1-36.4 years). Results: In total, 156 patients developed an AID, including 99 patients (10.9%) with nonhematologic AIDs, 46 (5.1%) with autoimmune cytopenia (AIC), and 11 (1.2%) with both; autoimmune hypothyroidism and psoriasis were the most frequent AIDs. Patients with nonhematologic AIDs had low-risk genetic features and were related to a better time to first treatment than patients with AIC (13.8 vs. 5.5 years; p <.001). Patients with both CLL and psoriasis had the lowest risk of progression. The authors performed a T-cell/natural killer-cell and cytokine assessment among patients who had CLL with and without psoriasis. An unsupervised hierarchical clustering revealed a distinct cluster characterized by an expansion of T-helper 17 cells, T-regulatory cells, interleukin-17F, and interleukin-23. Conclusions: The current findings suggest that nonhematologic AIDs are prevalent in patients with CLL, and these patients have a better prognosis than patients who have AIC. The expansion of interleukin-17F-producing cells in patients with psoriasis may explain their good prognosis.
Dipòsit Digital de Documents de la UAB
Publication

FcγRIIb-BCR co-ligation inhibits B-cell receptor signaling in chronic lymphocytic leukemia

  • Bosch, Rosa|||0000-0002-7596-183X
  • Mora, Alba|||0000-0003-1064-8495
  • Cuellar, Carolina
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Gorlatov, Sergey
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Montserrat, Emili
  • Sierra, Jorge|||0000-0002-7966-0356
  • Rai, Kanti R.
  • Chiorazzi, Nicholas
  • Moreno, Carol|||0000-0003-3275-0271
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies, Spanish Expert Consensus Recommendations

  • Boque, Concepcion
  • Sánchez Ramón, Silvia|||0000-0001-9585-6167
  • Córdoba, Raúl|||0000-0002-7654-8836
  • Moreno, Carol|||0000-0003-3275-0271
  • Cabezudo, Elena
A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; and to quantify serum IgG, IgA and IgM levels when SID is suspected. More than 90% agreed on the need for active immunization against seasonal influenza and H1N1, pneumococcus and Haemophilus influenzae. There was a consensus on the monitoring of IgG levels every 3 months (83%) and the need to have available a clinical protocol for the use of IVIG in the management of SID (94%), to monitor trough IgG levels to determine the correct IVIG dose (86%) and to discontinue IVIG after the recovery of IgG levels after 12 months of follow-up (77%). The findings of the present survey may be useful recommendations for hematologists and immunologists to improve the management of SID in daily practice.